<DOC>
	<DOC>NCT01074593</DOC>
	<brief_summary>The primary objective of this study is to compare the pharmacokinetic and pharmacodynamic effect of two commercial preparations of interferon beta-1a (IFN Test: Lab Bergamo and IFN Comparator: Rebif Â® - Merck Serono Lab) after single administration (12.000UI) in healthy subjects by modifying the parameters Cmax, Tmax and AUC (pharmacokinetics) and the levels of 2'5' oligoadenylate synthase and beta-2-microglobulin (pharmacodynamics).</brief_summary>
	<brief_title>Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects</brief_title>
	<detailed_description>Secondly, safety will be observed (tolerability) clinically after administration of a single dose in study subjects, by comparing the clinical and laboratory parameters before and after study and the incidence of adverse events.</detailed_description>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1. Accepted Informed Consent 2. Study subjects male, aged 18 to 50 years; 3. Research subjects with body mass index greater than or equal to 19 and less than or equal to 30; 4. Subjects considered healthy, based on the analysis of the clinical history and clinical and laboratory data. 1. Having donated or lost 450 mL or more of blood in the 6 months preceding the study; 2. Have participated in any experimental study or have ingested any drug trial in the 12 months preceding the start of the study; 3. Having made regular use of medication in the 4 weeks prior to the start of the study or have made use of medications that interfere with the pharmacokinetics / pharmacodynamics of drugs studied a week before the start of the study; 4. Have been hospitalized for any reason, up to 8 weeks before the start of the study; 5. Demonstrate a history of alcohol abuse, drugs, or drugs, or have consumed alcohol within 48 hours prior to the period of hospitalization; 6. Have a history of liver disease, renal, pulmonary, gastrointestinal, hematological or psychiatric; 7. To present the pressure of any etiology requiring pharmacological treatment; 8. Display history of myocardial infarction, angina and / or heart failure.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUG INTERFERON BETA-1A</keyword>
</DOC>